Skip to main content
Top
Published in: BMC Women's Health 1/2021

Open Access 01-12-2021 | Infertility | Research

Association of pelvic inflammatory disease (PID) with ovarian cancer: a nationwide population-based retrospective cohort study from Taiwan

Authors: Cherry Yin-Yi Chang, Kent Yu-Hsien Lin, Chien-Chu Huang, Wu-Chou Lin

Published in: BMC Women's Health | Issue 1/2021

Login to get access

Abstract

Background

Pelvic inflammatory disease (PID) is an important health issue for women. Infection and inflammation play an important role in carcinogenesis and PID has been reported to be associated with ovarian cancer in some small scale studies.

Aim

We sought to determine whether PID is associated with an elevated risk of ovarian cancer in Asian women.

Methods

Using data from Taiwan’s National Health Insurance Research Database (NHIRD), our retrospective cohort study included women diagnosed with PID (cases) between the years of 2000 till 2012. Each case was matched with two women without PID (controls) by age and the year of first entry into the database. Both study cohorts were followed-up until the first event of ovarian cancer, withdrawal from the NHI program, death, or the end of the study period (December 31, 2012). Cox proportional hazards regression models were used to estimate crude and adjusted hazard ratios (HRs and aHRs) with their corresponding 95% confidence intervals (95% CIs) for the association of PID and ovarian cancer risk, with and without adjusting for potential confounders.

Results

During an approximate 10 years of follow-up, cases were significantly more likely than controls to develop ovarian cancer (incidence rates of 0.27 and 0.16 per 1,000 person-years, respectively; P < 0.001). Women with a history of PID had a 1.49-fold elevated risk for ovarian cancer (aHR, 1.49; 95% CI, 1.21–1.84; P < 0.001).

Conclusion

Our study evidence supports the contention that PID increases the risk of developing ovarian cancer among Taiwanese women. Gynecologists should undertake careful assessments and closely follow patients with PID, who are at long-term risk of developing ovarian cancer. Our findings need further verification in other international cohorts.
Appendix
Available only for authorised users
Literature
1.
go back to reference Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines (2015). Reprod Endocrinol. 2015;24:51–6. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines (2015). Reprod Endocrinol. 2015;24:51–6.
2.
go back to reference Toth M, et al. Pregnancy outcome following pelvic infection. Infect Dis Obstet Gynecol. 1993;1(1):12–5.CrossRef Toth M, et al. Pregnancy outcome following pelvic infection. Infect Dis Obstet Gynecol. 1993;1(1):12–5.CrossRef
3.
go back to reference Westrom L. Effect of pelvic inflammatory disease on fertility. Venereology. 1995;8(4):219–22.PubMed Westrom L. Effect of pelvic inflammatory disease on fertility. Venereology. 1995;8(4):219–22.PubMed
4.
go back to reference Bender N, et al. Chlamydia infection, pelvic inflammatory disease, ectopic pregnancy and infertility: cross-national study. Sex Transm Infect. 2011;87(7):601–8.CrossRef Bender N, et al. Chlamydia infection, pelvic inflammatory disease, ectopic pregnancy and infertility: cross-national study. Sex Transm Infect. 2011;87(7):601–8.CrossRef
5.
go back to reference Bychkov V. Ovarian pathology in chronic pelvic inflammatory disease. Gynecol Obstet Investig. 1990;30(1):31–3.CrossRef Bychkov V. Ovarian pathology in chronic pelvic inflammatory disease. Gynecol Obstet Investig. 1990;30(1):31–3.CrossRef
6.
go back to reference Rasmussen CB, et al. Is pelvic inflammatory disease a risk factor for ovarian cancer? Cancer Epidemiol Biomarkers Prev. 2017;26(1):104–9.CrossRef Rasmussen CB, et al. Is pelvic inflammatory disease a risk factor for ovarian cancer? Cancer Epidemiol Biomarkers Prev. 2017;26(1):104–9.CrossRef
7.
go back to reference Rasmussen CB, et al. Pelvic inflammatory disease and the risk of ovarian cancer and borderline ovarian tumors: a pooled analysis of 13 case–control studies. Am J Epidemiol. 2017;185(1):8–20.CrossRef Rasmussen CB, et al. Pelvic inflammatory disease and the risk of ovarian cancer and borderline ovarian tumors: a pooled analysis of 13 case–control studies. Am J Epidemiol. 2017;185(1):8–20.CrossRef
8.
go back to reference Shen CC, et al. Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study. BMC Cancer. 2016;16(1):839.CrossRef Shen CC, et al. Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study. BMC Cancer. 2016;16(1):839.CrossRef
9.
go back to reference Goff BA, et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291(22):2705–12.CrossRef Goff BA, et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291(22):2705–12.CrossRef
10.
go back to reference Rossing MA, et al. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst. 2010;102(4):222–9.CrossRef Rossing MA, et al. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst. 2010;102(4):222–9.CrossRef
11.
go back to reference Doubeni CA, Doubeni AR, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Phys. 2016;93(11):937–44. Doubeni CA, Doubeni AR, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Phys. 2016;93(11):937–44.
12.
go back to reference Parazzini F, et al. Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1996;5(8):667–9.PubMed Parazzini F, et al. Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1996;5(8):667–9.PubMed
13.
go back to reference Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol. 1994;140(7):585–97.CrossRef Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol. 1994;140(7):585–97.CrossRef
14.
go back to reference Hartge P, et al. A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol. 1989;161(1):10–6.CrossRef Hartge P, et al. A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol. 1989;161(1):10–6.CrossRef
15.
go back to reference Franceschi S, et al. Risk factors for epithelial ovarian cancer in Italy. Am J Epidemiol. 1982;115(5):714–9.CrossRef Franceschi S, et al. Risk factors for epithelial ovarian cancer in Italy. Am J Epidemiol. 1982;115(5):714–9.CrossRef
16.
go back to reference Charbonneau B, et al. The immune system in the pathogenesis of ovarian cancer. Crit RevTM Immunol. 2013;33(2):137–64.CrossRef Charbonneau B, et al. The immune system in the pathogenesis of ovarian cancer. Crit RevTM Immunol. 2013;33(2):137–64.CrossRef
17.
go back to reference Tsai M-S, et al. Chang Gung Research Database: a multi-institutional database consisting of original medical records. Biomed J. 2017;40(5):263–9.CrossRef Tsai M-S, et al. Chang Gung Research Database: a multi-institutional database consisting of original medical records. Biomed J. 2017;40(5):263–9.CrossRef
18.
go back to reference Burkman RT. Reproductive hormones and cancer: ovarian and colon cancer. Obstet Gynecol Clin N Am. 2002;29(3):527–40.CrossRef Burkman RT. Reproductive hormones and cancer: ovarian and colon cancer. Obstet Gynecol Clin N Am. 2002;29(3):527–40.CrossRef
19.
go back to reference Abu-Rustum NR, Barakat RR, Curtin JP. Ovarian and uterine disease in women with colorectal cancer. Obstet Gynecol. 1997;89(1):85–7.CrossRef Abu-Rustum NR, Barakat RR, Curtin JP. Ovarian and uterine disease in women with colorectal cancer. Obstet Gynecol. 1997;89(1):85–7.CrossRef
20.
go back to reference Mori M, et al. Reproductive, genetic, and dietary risk factors for ovarian cancer. Am J Epidemiol. 1988;128(4):771–7.CrossRef Mori M, et al. Reproductive, genetic, and dietary risk factors for ovarian cancer. Am J Epidemiol. 1988;128(4):771–7.CrossRef
21.
go back to reference Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med. 2003;348(23):2339–47.CrossRef Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med. 2003;348(23):2339–47.CrossRef
22.
go back to reference Melin A, et al. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod. 2006;21(5):1237–42.CrossRef Melin A, et al. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod. 2006;21(5):1237–42.CrossRef
23.
24.
25.
go back to reference Lin HW, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol. 2011;12(9):900–4.CrossRef Lin HW, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol. 2011;12(9):900–4.CrossRef
26.
go back to reference Rasmussen CB, et al. Increased risk of borderline ovarian tumors in women with a history of pelvic inflammatory disease: A nationwide population-based cohort study. Gynecol Oncol. 2016;143(2):346–51.CrossRef Rasmussen CB, et al. Increased risk of borderline ovarian tumors in women with a history of pelvic inflammatory disease: A nationwide population-based cohort study. Gynecol Oncol. 2016;143(2):346–51.CrossRef
27.
go back to reference Zhou Z, et al. Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis. Cancer Causes Control. 2017;28(5):415–28.CrossRef Zhou Z, et al. Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis. Cancer Causes Control. 2017;28(5):415–28.CrossRef
28.
go back to reference Trabert B, et al. Antibodies against chlamydia trachomatis and ovarian cancer risk in two independent populations. J Natl Cancer Inst. 2019;111(2):129–36.CrossRef Trabert B, et al. Antibodies against chlamydia trachomatis and ovarian cancer risk in two independent populations. J Natl Cancer Inst. 2019;111(2):129–36.CrossRef
29.
go back to reference Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1995;4(5):447–51.PubMed Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1995;4(5):447–51.PubMed
30.
go back to reference Stewart LM, et al. Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer. Cancer Epidemiol. 2018;55:110–6.CrossRef Stewart LM, et al. Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer. Cancer Epidemiol. 2018;55:110–6.CrossRef
31.
go back to reference Zardawi IM. Primary fallopian tube carcinoma arising in the setting of chronic pelvic inflammatory disease. Case Rep Med. 2014;2014:645045.CrossRef Zardawi IM. Primary fallopian tube carcinoma arising in the setting of chronic pelvic inflammatory disease. Case Rep Med. 2014;2014:645045.CrossRef
32.
go back to reference Lipschutz DI. Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses’ Health Study. Obstet Gynecol. 2013;122(2 Part 1):395–6.CrossRef Lipschutz DI. Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses’ Health Study. Obstet Gynecol. 2013;122(2 Part 1):395–6.CrossRef
33.
go back to reference Evans EC, et al. Salpingo-oophorectomy at the time of benign hysterectomy: a systematic review. Obstet Gynecol. 2016;128(3):476–85.CrossRef Evans EC, et al. Salpingo-oophorectomy at the time of benign hysterectomy: a systematic review. Obstet Gynecol. 2016;128(3):476–85.CrossRef
34.
go back to reference Schmeler KM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354(3):261–9.CrossRef Schmeler KM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354(3):261–9.CrossRef
35.
go back to reference Park HK, et al. Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case-control study. Cancer Causes Control. 2018;29(11):1081–91.CrossRef Park HK, et al. Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case-control study. Cancer Causes Control. 2018;29(11):1081–91.CrossRef
36.
go back to reference Somigliana E, et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol. 2006;101(2):331–41.CrossRef Somigliana E, et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol. 2006;101(2):331–41.CrossRef
37.
go back to reference Ness RB, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol. 2002;155(3):217–24.CrossRef Ness RB, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol. 2002;155(3):217–24.CrossRef
38.
go back to reference Wallach EE, Bristow RE, Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril. 1996;66(4):499–507.CrossRef Wallach EE, Bristow RE, Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril. 1996;66(4):499–507.CrossRef
39.
go back to reference Wiesenfeld HC, et al. Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol. 2012;120(1):37–43.CrossRef Wiesenfeld HC, et al. Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol. 2012;120(1):37–43.CrossRef
Metadata
Title
Association of pelvic inflammatory disease (PID) with ovarian cancer: a nationwide population-based retrospective cohort study from Taiwan
Authors
Cherry Yin-Yi Chang
Kent Yu-Hsien Lin
Chien-Chu Huang
Wu-Chou Lin
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2021
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-021-01413-2

Other articles of this Issue 1/2021

BMC Women's Health 1/2021 Go to the issue